Ron Martell - 10 Jun 2024 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role
President, CEO and Director, Director
Signature
/s/ Herb Cross, as Attorney-in-Fact for Ron Martell
Issuer symbol
JSPR
Transactions as of
10 Jun 2024
Net transactions value
$0
Form type
4
Filing time
12 Jun 2024, 16:09:26 UTC
Previous filing
20 Feb 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JSPR Stock Option (right to buy) Award $0 +10,000 $0.000000 10,000 10 Jun 2024 Voting Common Stock 10,000 $23.95 Direct F1
transaction JSPR Performance Restricted Stock Units Award $0 +20,000 $0.000000 20,000 10 Jun 2024 Voting Common Stock 20,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option shall vest on June 10, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2 Represents a grant of performance-based restricted stock units ("PRSUs"), with each PRSU representing a contingent right to receive one share of common stock of the Issuer.
F3 If, by June 10, 2026, the closing price of the Issuer's common stock on the Nasdaq Capital Market is at or above $35.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days, all of the shares of the Issuer's common stock subject to the PRSUs shall vest in full on such thirtieth day, so long as the Reporting Person provides continuous services to the Issuer on and through the vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney